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Background: An evaluation of the 2010 ECDC guidance 
on HIV testing, conducted in October 2015–January 
2016, assessed its impact, added value, relevance 
and usability and the need for updated guidance. 
Methods: Data sources were two surveys: one for the 
primary target audience (health policymakers and 
decision makers, national programme managers and 
ECDC official contact points in the European Union/
European Economic Area (EU/EEA) countries and one 
for a broader target audience (clinicians, civil society 
organisations and international public health agen-
cies); two moderated focus group discussions  (17 
participants each); webpage access data; a literature 
citation review; and an expert consultation (18 par-
ticipants) to discuss the evaluation findings. Results: 
Twenty-three of 28 primary target audience and 31 of 
51 broader target audience respondents indicated the 
guidance was the most relevant when compared with 
other international guidance. Primary target audi-
ence respondents in 11 of 23 countries reported that 
they had used the guidance in development, moni-
toring and/or evaluation of their national HIV testing 
policy, guidelines, programme and/or strategy, and 
29 of 51 of the broader target audience respondents 
reported having used the guidance in their work. Both 
the primary and broader target audience considered it 
important or very important to have an EU/EEA-level 
HIV testing guidance (23/28 and 46/51, respectively). 
Conclusion: The guidance has been widely used to 
develop policies, guidelines, programmes and strat-
egies in the EU/EEA and should be regularly updated 
due to continuous developments in the field in order to 
continue to serve as an important reference guidance 
in the region.
Introduction 
According to the 2015 joint European Centre for Disease 
Prevention and Control (ECDC) and World Health 
Organization (WHO) HIV surveillance report, rates of 
HIV testing among populations most at risk of HIV in 
the WHO European Region were low overall, and hence, 
a considerable proportion of people who are infected 
with HIV are not aware of being infected [1]. This means 
that many who need treatment are not receiving it 
because they have not been diagnosed and linked to 
care. In addition, rates of late diagnosis of HIV were 
high at 47%, among newly diagnosed in 2015 which 
has not changed significantly in the European Union/
European Economic Area (EU/EEA) since 2010 [1,2]. 
Earlier diagnosis enables people to start treatment 
early, which increases their chances of normal life 
expectancy and healthier life while reducing the risk of 
onward transmission [1].
Increasing the availability, accessibility and uptake of 
HIV testing is critical to reduce the number of people 
who do not know their HIV status or who are diagnosed 
late. With the ambitious goals of 90–90–90 set by the 
UNAIDS, the first 90 means that 90% of people living 
with HIV should know their status [3]. However, target-
ing HIV testing programmes to those who are most at 
risk remains a challenge in many countries in the EU/
EEA. Monitoring HIV testing coverage is patchy and het-
erogeneous, making it hard to assess trends over time 
at EU/EEA level and to provide useful data to inform 
action [4]. A small increase in the total number of tests 
performed has been seen overall, while some coun-
tries have shown larger increases in testing [5].
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ECDC published a commissioned guidance in 2010 [6], 
together with the literature review that provided the 
evidence base [7]. The guidance intended to inform the 
development, monitoring and evaluation of national 
HIV testing strategies and programmes in the EU/EEA. 
It included the following topics: (i) core principles for 
national HIV testing strategies and programmes, (ii) 
developing a national HIV testing strategy, (iii) ensur-
ing access to HIV treatment, care and prevention, and 
(iv) monitoring and evaluation. Its target audience 
was health policymakers and decision makers in EU/
EEA countries, national programme managers and 
coordinators, ECDC national focal points (nominated 
ECDC contact points responsible for strategic and 
operational collaboration on technical and scientific 
issues) and disease network experts. Since 2010, the 
HIV testing landscape has evolved with new evidence 
and results for example on indicator condition guided 
HIV testing [8,9], when to start treatment, self-testing 
and home sampling, and additional guidelines have 
subsequently been published, some more up to date 
such as those by WHO in 2015 [10], the International 
Union against Sexually Transmitted Infections (IUSTI) 
[11] and the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) [12].
Our aim was to evaluate the use and impact of the 
ECDC HIV testing guidance in the EU/EEA in order to 
make recommendations for future steps by ECDC in this 
area, including the potential need for an updated guid-
ance. Our objective was to assess (i) awareness of the 
guidance among the primary target audience and the 
broader target audience, (ii) the relevance and usabil-
ity of the guidance for the primary target audience and 
the broader target audience, (iii) the extent to which 
the guidance has added value to or complemented 
existing documents and (iv) the impact of the guidance 
on supporting the development, monitoring and evalu-
ation of national HIV testing strategies or programmes 
in the countries.
Methods 
The evaluation was conducted between October 2015 
and January 2016. Data were collected through: two 
evaluation surveys; two moderated focus group dis-
cussions; webpage access data; a literature citation 
review; and an expert consultation hosted by ECDC 
to discuss the evaluation findings as well as to vali-
date and interpret the results. The two surveys were 
one for the primary target audience for the guidance, 
consisting of health policymakers and decision mak-
ers, national programme managers and ECDC official 
contact points in the 31 EU/EEA countries and one for 
the broader audience, including clinicians, civil society 
organisations and international agencies.
Evaluation surveys
Survey questions were designed to address the aims 
and objectives of the evaluation. To contextualise 
the use and impact of the guidance, the surveys 
asked about existing national HIV testing guidelines, 
Figure 
Country location of survey respondents and their role in 
developing national HIV policy/guidelines, ECDC HIV 
testing guidance evaluation, October 2015–January 2016 
(n=23 EU/EEA countries)
A. Primary target audience
B. Broader target audience
Response
No response
Y - Participated in developing national policy/guidelines
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y, N
N
Y,Y,Y,Y,Y,
N,N,N,N,N
Y,Y,Y,Y,Y
Y
Y
Y
Y
Y, Y
Y, Y, Y
Y,Y,Y,Y,
N,N,NY,YN,N,
N,N
N
N
N
N
N
N, N
Y, Y, N
N
N
N
N
N
N
N,N
Y, Y
Y,Y
N - Did not participate in developing national policy/guidelines
Response
No response
Y - Participated in developing national policy/guidelines
N - Did not participate in developing national policy/guidelines
ECDC: European Centre for Disease Prevention and Control; EU/EEA: European 
Union/European Economic Area.
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programmes and services. They included questions 
with both pre-defined answer categories and free text 
fields to allow the respondents to qualify and further 
explain their answers. The two surveys were similar 
except for five questions on national-level HIV testing 
policies and programmes which were not included in 
the one to the broader audience. Surveys were set up 
in a secure, web-based application designed to sup-
port data capture for research studies (REDCap). They 
were piloted across five countries. Five people piloted 
the survey for the primary target group (from Estonia, 
Greece, Norway and the United Kingdom (UK)) and 
three the survey for the broader target group (from 
Spain and UK). The feedback was incorporated into the 
final versions of the two surveys.
Primary target audience respondents were identified 
using a purposive sampling approach to ensure that 
there was at least one respondent from each EU/EEA 
country. Potential respondents were identified by the 
official ECDC Coordinating Competent Bodies and 
National Focal Points for HIV in each country, with 
priority given to policymakers, advisors and technical 
experts at a national level with responsibility for and 
expertise in HIV testing and guidance development 
and implementation. For the countries that did not 
nominate respondents, the survey was sent directly 
to National Focal Points for HIV. The broader audience 
survey was distributed widely through mailing lists of 
HIV organisations and professional networks and sent 
to individual experts known to be working in the field 
of HIV. The target was to receive 150 responses.
The survey data were extracted in Excel format from 
REDCap and descriptive statistics were produced as 
frequencies and respective proportions in Excel.
Focus group discussions
Two focus group discussions of one hour each were 
conducted in October 2015 during the European AIDS 
Clinical Society (EACS) conference in Barcelona, Spain. 
A total of 17 participants from six countries took part 
in the two discussions. A semi-structured interview 
guide was developed to lead the focus group discus-
sions and ensure coverage of the evaluation objectives 
(e.g. Do you consider there is added value at EU/EEA 
level of having an ECDC HIV testing guidance? If so, in 
what way?). The data were analysed using a deductive 
approach and the research questions were the basis 
for grouping data according to themes, similarities and 
differences, resulting in a descriptive content analysis.
Webpage access data and review of 
literature citation
An analysis of traffic related to the page on the ECDC 
website hosting the guidance was performed in January 
2016. The analysis covered the period from January 
2014 and onwards due to a platform migration of ECDC 
landing page in 2013. It captured the number of page 
views, sources of traffic and access country.
Citation screening was conducted to identify relevant 
citations of the guidance. Searches in Scopus and 
Google Scholar were performed on 8 January 2016 to 
retrieve articles and documents in all languages cit-
ing the guidance in the period December 2010 to end 
December 2015 using words of the title in the ‘refer-
ences’ field and parts of the URL in the ‘website’ tag in 
the advanced search in Scopus.
Expert consultation
An Expert Panel was established by ECDC to provide 
expert opinion on the validation, interpretation and 
presentation of the findings from the evaluation and to 
Table 1
HIV testing in the countries of the primary target audience respondents, ECDC HIV survey, October 2015–January 2016 
(n = 23 EU/EEA countries)
Characteristics of HIV testing policy and practices Total (n=23)
National HIV testing programme 7
Including national HIV testing monitoring and evaluation plan 4a
Testing programmes and services at sub-national level 7a
No national HIV testing programme but health system that conducts HIV testing 9
Elements included in HIV testing practices based on reported frequency (most and least)
Post-test access to treatment, care and prevention services 17
Voluntary, confidential testing with informed consent 16
Testing of all pregnant women for HIV (opt-out) 16
Dedicated HIV testing centres (e.g. for people at high risk, PWID services) 15
Routine offering in emergency departments 4
Written informed consent 2
Home testing/self-testing 1
ECDC: European Centre for Disease Prevention and Control; EU/EEA: European Union/European Economic Area; PWID: people who inject drugs.
a Only those seven reporting having a national HIV testing programme were asked this question.
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contribute to the identification of priorities for actions 
and next steps for ECDC in the area of HIV testing in 
the EU/EEA. The Expert Panel consisted of 18 members 
from 14 countries, representing various constituen-
cies including national public health bodies, clinical 
societies, academia, civil society and international 
organisations.
Results 
Evaluation surveys
Twenty-eight respondents from 23 of 31 EU/EEA MS 
completed the primary target audience survey (Figure). 
Five countries submitted surveys from two respond-
ents. Where the answers were conflicting, responses 
were analysed in more depth, taking into account the 
background of the respondents. Fifty-one respondents 
from 18 EU/EEA countries and one multinational organ-
isation (WHO) completed the survey for the broader 
audience (Figure). 
National guidelines and programmes
The primary target audience provided background 
information on the general use of national reference 
documents on testing. The most used documents were 
national HIV strategy/policy documents that include 
recommendations on testing (18/28), national HIV 
testing guidelines (14/28) and HIV testing guidelines 
issued by professional societies (13/28). Different lev-
els of HIV testing programmes were reported by the 
respondents (Table 1).
Awareness of the ECDC HIV testing guidance
All 28 primary target audience respondents and 42 of 
51 respondents of the broader target audience respond-
ents were aware of the ECDC HIV testing guidance.
The guidance had a total of 619 page views (530 unique 
views) on the ECDC website and was cited in the litera-
ture 79 times: 74 times in scientific journals (original 
articles (n=65), reviews (n=4), editorials (n=3), com-
mentaries (n=1) letters (n=1)), three times in reports, 
and once in a book and in a thesis, respectively. In 
six of these, ECDC staff was a first author. Half of the 
citations (40/79; 51%) reported or referenced the rec-
ommendations or core principles in the guidance.
Relevance and usability of the guidance
Twenty-three of the 28 primary target audience respond-
ents and 31 of the 51 broader target audience respond-
ents indicated the guidance as being the most relevant 
in their respective context when compared with other 
international guidance such as the WHO 2015 guide-
lines [10], IUSTI 2014 guidelines [11] and EMCDDA 2010 
guidance [12]. The majority reported that the guidance 
was relevant when it was published in 2010 and that it 
remains relevant today.
For the primary target audience, the guidance was 
mainly considered relevant as a reference policy docu-
ment (18/21), for use in national HIV testing policy/
guidelines/strategy development, monitoring and/
or evaluation (16/21), and for general information on 
approaches to HIV testing (16/21).
For the broader target audience, the guidance was 
mainly considered relevant as a reference policy docu-
ment (19/30), for general information on approaches to 
HIV testing (17/30), and for support for advocacy work 
on HIV testing to influence decision makers and raise 
awareness (16/30).
In terms of usability, the majority of both groups of 
respondents strongly agreed or agreed that the guid-
ance is (i) user-friendly (primary target audience: 16/23; 
broader target audience: 33/51), (ii) clearly written and 
easy to understand (primary target audience 22/23; 
broader target audience 39/51), (iii) easily accessible 
(primary target audience 21/23; broader target audi-
ence 31/51) and (iv) includes enough details about HIV 
testing (primary target audience 16/23; broader target 
audience 31/51).
Added value of the guidance
Twenty-three of 28 primary target audience respond-
ents and 46 of 51 broader target audience respondents 
considered it very important or important to have EU 
level HIV testing guidance (Table 2).
Respondents highlighted a number of ways in which 
they saw the ECDC guidance to add value and to influ-
ence change in individual countries. For the primary 
target audience, the guidance mainly adds value by 
providing a well-recognised policy reference docu-
ment (18/25), by providing an EU standard (15/25) and 
by saving time and resources as it provides an up to 
date review of evidence that is relevant to the EU/EEA 
(15/25).
For the broader target audience, the main added value 
of the guidance is influencing the development of 
national policies (35/50).
Table 2
Importance of having an EU/EEA-level guidance by target 
audience, ECDC HIV survey, October 2015–January 2016 
(n = 23 EU/EEA countries)
Importance of having an EU/
EEA- level guidance
Primary target 
audience (n=28)
Broader target 
audience 
(N=51)
Very important 9 28
Important 14 18
Somewhat important 2 4
Not important 1 1
No response 1 0
ECDC: European Centre for Disease Prevention and Control; EU/EEA: 
European Union/European Economic Area.
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Use and impact of the guidance
Almost half of the countries (10/23) reported having 
used the guidance in the development, monitoring 
and/or evaluation of their national HIV testing policy/
guidelines/programme/strategy. Of the broader target 
audience respondents, 29 of 51 reported having used 
the guidance for their work. The respondents who 
reported having used the guidance were then asked to 
report how they had used it (Table 3).
Twenty of the 28 primary target audience respondents 
and 38 of the 51 broader target audience respondents 
reported changes in HIV testing practices in their coun-
try since 2010. Of these, 16 of 20 and 16 of 38, respec-
tively, reported that in their opinion these changes led 
to an improvement in HIV testing in their country. The 
guidance was considered as having directly influenced 
these changes by seven of the 20 primary target audi-
ence respondents and nine of the 38 broader target 
audience respondents.
Updating and revising the guidance
Twenty-six of 28 respondents highlighted at least one 
new area/topic that should be added in a new guid-
ance document. The need to update the HIV testing 
guidance due to significant new developments within 
the HIV testing field, was also confirmed in the focus 
group discussions. An updated guidance should have a 
greater focus on monitoring and evaluation of HIV test-
ing programmes and services and include examples of 
best practice to help foster effective implementation. 
In addition, focus group discussions highlighted the 
fact that future testing guidance should also embrace a 
broader target audience, to also take account of those 
involved in guidance development and implementation 
within and outside of the EU/EEA.
Discussion 
This study attempted to assess the impact of the ECDC 
HIV testing guidance 5 years after its release, using a 
multidisciplinary approach. The findings indicate there 
is a high level of awareness of the guidance, that it has 
reached a wider audience than the intended audience, 
that it is perceived to be relevant and useful, and that 
it adds value by providing an EU/EEA-wide perspective. 
The guidance has been widely used to develop and 
revise national policies, guidelines, programmes and 
strategies as well as to support monitoring and evalu-
ation and advocacy, and has contributed to changes in 
HIV testing strategies in a number of EU/EEA countries.
There is, however, a lack of data on HIV testing cover-
age and uptake, and of standardised data in particular. 
This makes it difficult to accurately measure changes 
in testing across the EU/EEA over time but the limited 
improvements described in testing rates and in the num-
ber of late presenters [13] suggest that testing policies 
and guidelines are not being implemented effectively. 
For example, the ECDC 2010 guidance emphasises the 
need for scaling up indicator condition guided HIV test-
ing and community-based testing, which are the focus 
of a number of recent initiatives and projects in Europe, 
including the EU funded OptTEST [14], Euro HIV EDAT 
and COBATEST [15] projects.
Despite this, recent data show that indicator condition 
guided HIV testing [8,16] is not being widely imple-
mented in Europe. The OptTEST project has reviewed 
national HIV testing guidelines and audited imple-
mentation of indicator condition guided HIV testing in 
seven pilot countries. The results show low rates of HIV 
testing in patients presenting with indicator conditions 
as well as sub-optimal inclusion of indicator condition 
guided testing recommendations both in national HIV 
testing guidelines and relevant specialty guidelines 
[17,18].
Community-based testing has been expanded in the 
EU/EEA since 2010 through a variety of service deliv-
ery models [19]. However, limited funding, poor inte-
gration with national HIV programmes and regulatory 
barriers in some cases (for example, restricting testing 
to trained health professionals), have hindered further 
scale up [4,20]. These findings reinforce the need for 
guidance to clearly address these implementation chal-
lenges, including through direct guidance in relation to 
engagement with the broader target audience. There 
is a need to assist countries to a greater extent in the 
development of national policies, their implementation 
and evaluation and to support them when undertak-
ing future revisions. The focus group discussions con-
firmed this need.
This assessment has shown that the guidance has suc-
cessfully reached a wider audience than the intended 
Table 3
Reported use of the ECDC HIV testing guidance of those 
who reported guidance use by target audience, ECDC HIV 
testing guidance evaluation, October 2015–January 2016 
(n = 23 EU/EEA countries)
Use of the guidance
Primary 
target 
audience 
(n = 10)
Broader 
target 
audience 
(n = 29)
To revise an existing HIV testing 
document 6 19
To support/inform the monitoring/
evaluation of HIV testing 5 9
To develop a new HIV testing 
document 3 12
To advocate for HIV testing, raise 
awareness of HIV testing 3 18
To fundraise/mobilise resources for 
HIV testing programmes 2 13
Other 2 1
To influence decision makers NA 4
ECDC: European Centre for Disease Prevention and Control; EU/EEA: 
European Union/European Economic Area; NA: not applicable.
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one. This observation may reflect the broadening range 
of stakeholders involved in health policy and decision 
making at least in some countries, as well as of health-
care workers involved in delivery of HIV testing ser-
vices. The lessons learned from this evaluation should 
be used to inform future evaluations as well as the 
development of potential new guidance.
This evaluation had some limitations. Different sam-
pling methods were used for the respondents of the 
two groups for the survey and for the focus groups, 
each with its own potential selection bias. Selection 
bias may have occurred when identifying participants, 
and despite a relatively high response rate, there is 
still an issue with non-respondents among the primary 
target audience, with those who are more familiar with 
the guidance potentially being more likely to respond to 
the survey. Acquiescence bias may also have occurred 
as the primary target audience was mainly comprised 
of ECDC contact points. The broader target audience 
was selected via convenience sampling through mailing 
list contacts and the number of responses was much 
lower than anticipated. The questions and response 
categories in the surveys were mostly pre-defined and 
some topics or issues may not have been captured or 
misinterpreted by the respondents. Finally, the results 
are primarily based on opinion and self-reported data 
in the survey responses. The citation review was lim-
ited as it was only performed in Scopus and Google 
Scholar. References to the guidance in national or sub-
national policy documents or similar grey literature 
were therefore not captured so, the use of the guidance 
to inform national policy is likely to be under reflected 
in the citation review. The website access analysis was 
constrained by limited data availability due to a plat-
form migration and other technical challenges, which 
again are likely to have resulted in an underestimation 
of the true number of page views and downloads.
Conclusions
Three key elements emerged from this evaluation exer-
cise: (i) the need to update the content of HIV testing 
guidance at more frequent intervals to capture evolving 
and accumulating evidence in the field, (ii) the value of 
engaging different constituencies and relevant organi-
sations such as WHO, non-governmental and civil 
society organisations, clinical specialties and profes-
sional societies in a collaborative approach to foster 
HIV testing coverage and diversify the offer of testing 
modalities uptake and (iii) monitoring and evaluation 
of testing initiatives is considered an area for further 
development to devise a robust and standardised 
framework that can be used in the EU/EEA. Guidance 
of this sort should contribute to strengthen efforts to 
increase coverage, uptake of HIV testing and access to 
testing through diversification of delivery channels.
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